138 related articles for article (PubMed ID: 12113067)
1. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
[TBL] [Abstract][Full Text] [Related]
2. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
5. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
Kobayashi M; Kuramoto H; Ota J; Fujimoto N
Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal chemotherapy for hormone-refractory prostate cancer].
Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
[TBL] [Abstract][Full Text] [Related]
9. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
10. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
11. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.
Suzuki M; Mamun MR; Hara K; Ozeki T; Yamada Y; Kadowaki T; Honda H; Yanagihara Y; Ito YM; Kameyama S; Ohta N; Hosoi T; Arai T; Sawabe M; Takeuchi T; Takahashi S; Kitamura T
Eur Urol; 2005 Nov; 48(5):752-9. PubMed ID: 16126332
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
Noguchi M; Kakuma T; Uemura H; Nasu Y; Kumon H; Hirao Y; Moriya F; Suekane S; Matsuoka K; Komatsu N; Shichijo S; Yamada A; Itoh K
Cancer Immunol Immunother; 2010 Jul; 59(7):1001-9. PubMed ID: 20146063
[TBL] [Abstract][Full Text] [Related]
14. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
15. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis.
Lubiniecki GM; Berlin JA; Weinstein RB; Vaughn DJ
Cancer; 2004 Dec; 101(12):2755-9. PubMed ID: 15536625
[TBL] [Abstract][Full Text] [Related]
17. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
18. The use of estramustine phosphate in the modern management of advanced prostate cancer.
Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
[TBL] [Abstract][Full Text] [Related]
19. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
20. The present role of estramustine phosphate in advanced prostate cancer.
Van Poppel H; Baert L
Prog Clin Biol Res; 1991; 370():323-41. PubMed ID: 1924466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]